Akebia Therapeutics, Inc. business relationships
Companies named in Akebia Therapeutics, Inc.’s 10-K filed 2026-02-26, and public companies whose annual reports name Akebia Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.6 / 10
- AI naming
- 4 / 100 Top 3% in its category
- Agent readiness
- 35 / 100
- AI adoption
- 0 / 100
Named in Akebia Therapeutics, Inc.’s annual report 8
“On February 18, 2022, we entered into a Second Amended and Restated License Agreement, or the Vifor License Agreement , with Vifor (International) Ltd. (now a part of CSL Limited), or CSL Vifor , which amended and restated the License Agreement dated as of May 12, 2017.” SEC filing
“The Vifor License Agreement granted CSL Vifor an exclusive license to sell Vafseo to Fresenius Medical Care North America and its affiliates, including Fresenius Kidney Care Group LLC, to certain third-party dialysis organizations approved by us, to independent dialysis organizations that are member...” SEC filing
“In March 2020, the Company entered into a Supply Agreement with Patheon Inc., or Patheon , or the Patheon Agreement , under which Patheon agreed to manufacture Vafseo drug product for commercial use under a volume-based pricing structure through June 30, 2023, with the agreement renewing annually un...” SEC filing
“We also utilize third parties for the commercial distribution of Auryxia and Vafseo, including Cardinal Health, Inc. as the exclusive third-party logistics provider, or 3PL , wholesale distributors and certain specialty pharmacy providers.” SEC filing
“In June 2021, we licensed praliciguat from Cyclerion Therapeutics, Inc., or Cyclerion , via an exclusive global license, which includes certain intellectual property rights to research, develop and commercialize the asset.” SEC filing
“Amended and Restated Sub-License Agreement, dated June 8, 2009, as amended by the First Amendment thereto, dated June 12, 2013, by and between Keryx Biopharmaceuticals, Inc., Japan Tobacco, Inc. and Torii Pharmaceutical Co., Ltd” SEC filing
“Under the Manufacture and Supply Agreement with BioVectra, Inc., or BioVectra , and the Amended and Restated Product Manufacture and Supply and Facility Construction Agreement with BioVectra, the Company agreed to purchase minimum” SEC filing
“On February 5, 2025, we entered into an Authorized Generic Distribution and Supply Agreement with Mylan Pharmaceuticals, Inc., as amended in September 2025, pursuant to which, they are currently selling an authorized generic version of Auryxia.” SEC filing
Companies whose annual reports name Akebia Therapeutics, Inc. 1
“On June 3, 2021, Cyclerion entered into a license agreement with Akebia Therapeutics Inc. ("Akebia") relating to the exclusive worldwide license to Akebia of our rights to the development, manufacture, medical affairs and commercialization of pharmaceutical products containing praliciguat and other...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.